The scale of the underlying problem is enormous. Hospitalizations related to alcohol use disorder and opioid use disorder contribute to substantial illness and rising costs, collectively amounting to nearly 50 billion dollars in healthcare spending in 2022 alone. Randomized trials have long supported the use of guideline-recommended medications for these conditions, which meaningfully reduce alcohol or opioid use and improve treatment retention among patients with opioid use disorder. Observational studies have also suggested that these medications could reduce acute healthcare utilization, such as emergency department visits and hospital admissions. Against that evidence base, the treatment rates reported in national surveys are strikingly low: in 2025, only about 3 percent of Americans aged 12 years and older with alcohol use disorder reported receiving medication treatment, and only 16 percent of those with opioid use disorder reported receiving medication in the past year.

Pham and colleagues addressed the relationship between medication use and healthcare utilization using a cross-sectional analysis of US adults from the 2022–2023 National Survey on Drug Use and Health, a nationally representative survey that assesses substance use disorders based on formal diagnostic criteria. Their weighted sample represented 57.5 million adults with past-year alcohol use disorder and 2.9 million adults with past-year opioid use disorder. Within that population, only 2 percent of those with alcohol use disorder and 30 percent of those with opioid use disorder reported using medication treatment within the past year. Perhaps the most consequential single number in the analysis is this: among patients who did not receive medication treatment, the mean number of past-year outpatient visits was 3.3. In other words, many untreated patients were already seeing doctors regularly, which suggests that lack of contact with the healthcare system is not the primary barrier keeping them from evidence-based pharmacotherapy.

The utilization findings themselves were nuanced and, at first glance, counterintuitive. In stratified analyses, healthcare utilization was generally more frequent among patients who received medications for alcohol use disorder, but no consistent association emerged for those who received medications for opioid use disorder. In unadjusted analyses of patients with alcohol use disorder, past-year medication use was associated with more emergency department visits, with an incidence rate ratio of 3.10 (95 percent confidence interval 1.98–4.83), more nights hospitalized, with an incidence rate ratio of 4.10 (95 percent confidence interval 2.17–7.75), and more outpatient visits, with an incidence rate ratio of 1.76 (95 percent confidence interval 1.18–2.62). When the analysts controlled for sociodemographic factors and comorbidities, the associations with emergency department visits and nights hospitalized remained statistically significant but attenuated, at 1.91 (95 percent confidence interval 1.19–3.06) and 2.03 (95 percent confidence interval 1.09–3.79) respectively, while the association with outpatient visits was no longer significant at 1.22 (95 percent confidence interval 0.91–1.63).

For patients with opioid use disorder, the picture was different. The only significant adjusted association between medication treatment and healthcare utilization was for nights hospitalized, with an incidence rate ratio of 2.08 (95 percent confidence interval 1.22–3.55). The divergence between the two conditions is one of the study’s most intriguing puzzles, and the cross-sectional design of the dataset precludes any definitive explanation. One possibility is that patients with alcohol use disorder are offered treatment later in the course of their disease, after alcohol-associated chronic medical conditions have already developed that predispose them to higher rates of healthcare utilization. Another possibility is that the findings reflect a genuine differential effect of medication treatment across the two conditions, given that medications for opioid use disorder are generally considered more effective than those for alcohol use disorder. It also remains unknown how utilization differs depending on which specific medication is initiated and whether psychosocial treatments are delivered concurrently across different medical settings.

The demographic profile of who received treatment adds an important layer of interpretation. Adults who received medications were generally older and more socioeconomically disadvantaged than those who did not: they were less often married, less educated, more often unemployed, and had lower incomes. They also carried more medical comorbidities and had greater severity of their alcohol or opioid use disorder. To some extent, this pattern is reassuring, because it indicates that medications are reaching the population with the highest degree of social vulnerability and clinical need—the patients who stand to benefit from them the most. On the other hand, it suggests that patients are often not receiving treatment earlier in their disease course, at a point when intervention could prevent the downstream social and medical consequences of untreated addiction before they accumulate.

That late start may also help explain another persistent problem: extremely poor persistence with these medications. Prior research has documented high rates of discontinuation of medications for alcohol use disorder and limited retention in buprenorphine treatment for opioid use disorder. The greater socioeconomic disadvantage and disease severity observed among treated patients may themselves act as barriers to staying on treatment, compounding the challenge of retention. This points toward structured interventions that address social vulnerability directly—such as care navigation programs that help patients overcome logistical, financial, and coordination obstacles—as potentially necessary complements to medication prescribing if treatment is to be sustained over time.

Several methodological limitations shape how these findings should be read. Because the study is cross-sectional, the timing of medication use relative to healthcare encounters cannot be determined: it is impossible to know whether healthcare encounters preceded or followed medication initiation, so no causal relationship can be ascribed to the observation that patients receiving medications for alcohol use disorder had higher utilization. The utilization outcomes were self-reported and therefore prone to recall bias, a common trade-off in addiction health services research. National surveys like the National Survey on Drug Use and Health rely on self-reported data, but that approach yields reliable population-level prevalence estimates based on formal diagnostic criteria. Administrative data, by contrast, are compromised by selective and non-standardized screening for alcohol and opioid use disorder in many health systems, which makes case ascertainment less reliable. Future studies could explore novel data linkages or health systems with more standardized screening and documentation procedures to close this gap.

A final interpretive caution concerns the meaning of healthcare utilization itself. Even acute utilization is context-dependent and does not inherently represent a negative outcome. For a patient with an acute health condition, presenting to the emergency department may be a desirable outcome rather than a failure, particularly compared with delaying care and risking disease progression. The survey data used in this study cannot identify which healthcare encounters were preventable or directly attributable to alcohol or opioid use disorder, so higher utilization among treated patients cannot be automatically framed as harm or as treatment failure.

What the study cannot do is establish the effect of these medications on healthcare utilization, and the editorial emphasizes that any interpretation must be situated within decades of randomized trial evidence demonstrating meaningful clinical benefit. What the study does provide is a stark reminder of underutilization—even among patients who are already engaged with the healthcare system and seeing clinicians multiple times a year. The path forward, the editorial argues, lies in high-quality hybrid effectiveness-implementation trials that test strategies to increase uptake of medications for alcohol and opioid use disorder across emergency departments, inpatient wards, and outpatient settings, while simultaneously assessing clinical outcomes including subsequent healthcare utilization. With nearly 50 billion dollars in annual spending tied to alcohol- and opioid-related hospitalizations and treatment rates stuck in the single digits for alcohol use disorder, the economic and human stakes of closing that gap could hardly be higher.

Subject of Research: The association between medications for alcohol and opioid use disorder and healthcare utilization among US adults

Article Title: What is the Relationship Between Addiction Medications and Healthcare Utilization?

Article References: Bernstein, E. Y. (2026). What is the Relationship Between Addiction Medications and Healthcare Utilization?. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10885-7

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10885-7

Keywords: alcohol use disorder, opioid use disorder, medication treatment, healthcare utilization, NSDUH, emergency department visits, hospitalization, treatment retention, addiction medicine, health services research, Journal of General Internal Medicine, treatment gap

The research team, led by emergency physician Hazar Khidir of Henry Ford Hospital and including investigators at Stanford University, the University of Washington, and Yale University, assembled one of the largest cohorts ever used to study this question. Drawing on 100 percent Medicaid claims files from 2016 through 2019, they identified 234,944 acute opioid-related events among 169,721 beneficiaries aged 18 to 64. To qualify, an encounter had to involve a nonfatal emergency department visit, an acute inpatient admission, or an inpatient rehabilitation or detoxification stay tied to opioid overdose, opioid withdrawal, or an infection caused by injection drug use. These are precisely the clinical junctures that addiction medicine specialists call teachable moments, when a patient has survived an overdose or been hospitalized for a serious infection and may be uniquely receptive to starting treatment.

The technical design of the study matters for interpreting its results. The researchers tracked three primary outcomes: whether patients filled a buprenorphine prescription within 30 days of discharge, whether they filled a naloxone prescription, the nasal spray that reverses opioid overdoses, within the same window, and whether they achieved what the field calls buprenorphine retention, defined as at least 150 days of the medication on hand within 180 days of the encounter. They also examined early engagement, measured as fills within just three days. To isolate the effect of race and ethnicity from other factors, the team used hierarchical logistic regression, a statistical approach well suited to claims data because it accounts for patients being clustered within states and years. The models adjusted for age, sex, comorbid medical conditions, prior treatment history, the specific diagnosis that brought the patient in, the state of residence, and the calendar year.

The baseline numbers alone are sobering. Across all 234,944 events, only 14.08 percent of patients filled a buprenorphine prescription within 30 days, and just 3.78 percent filled naloxone. Only 4.62 percent were retained on buprenorphine at 180 days. In other words, after surviving an overdose or being hospitalized for a life-threatening infection from injection drug use, fewer than one in seven Medicaid beneficiaries started the medication most strongly associated with keeping them alive, and fewer than one in twenty stayed on it long enough to derive its full protective effect. The cohort was 68.1 percent White, 11.5 percent Black, and 11.1 percent Hispanic, with a mean age of 37.48 years and 43.36 percent female.

When the researchers compared racial and ethnic groups after statistical adjustment, the disparities emerged clearly and consistently. Compared with non-Hispanic White patients, Black patients had significantly lower adjusted odds of filling buprenorphine within 30 days across every setting studied: the odds were 21 percent lower after emergency department visits (adjusted odds ratio 0.79, 95 percent confidence interval 0.71 to 0.88), 28 percent lower after inpatient admissions (0.72, 0.63 to 0.83), and 17 percent lower after rehab or detox stays (0.83, 0.71 to 0.97). Hispanic patients fared similarly, with 20 percent lower odds after emergency visits (0.80, 0.73 to 0.88) and 17 percent lower odds after inpatient admissions (0.83, 0.75 to 0.93). These are not marginal differences confined to one corner of the health system; they span the entire acute care continuum.

The retention findings were even more alarming. Among patients who did manage to start buprenorphine, Black patients had 36 percent lower adjusted odds of being retained at 180 days after an emergency department encounter (0.64, 0.55 to 0.74), 49 percent lower odds after an inpatient stay (0.51, 0.43 to 0.60), and 37 percent lower odds after rehab or detox (0.63, 0.48 to 0.82). Hispanic patients showed 30 percent lower odds after emergency visits (0.70, 0.62 to 0.79) and 34 percent lower odds after inpatient admissions (0.66, 0.56 to 0.78). An odds ratio of 0.51 means that, after accounting for every measured confounder, a Black patient hospitalized for an opioid-related crisis had roughly half the chance of a comparable White patient of still being on medication six months later. Retention is the single most important predictor of buprenorphine’s mortality benefit; studies have shown that interruptions in medication dramatically raise overdose risk.

The study’s focus on Medicaid is deliberate and consequential. Medicaid is the dominant payer for people with opioid use disorder in the United States, covering a population that bears a disproportionate share of the overdose burden. Because the program insures patients across state lines and across every type of acute care setting, it offers a rare, near-complete window into how the treatment system actually performs. Prior work had already documented a racial divide in buprenorphine access: a 2023 analysis in the New England Journal of Medicine found racial inequality in the receipt of medications for opioid use disorder, and studies of emergency departments across five health systems showed that Black patients were less likely to be started on buprenorphine during their visits. The new study extends that evidence to the post-discharge period and to inpatient and detoxification settings, using a multi-state design that rules out the possibility that the gaps are an artifact of any single state’s policy or any single hospital’s practice.

Why do these disparities persist even after adjusting for diagnosis, comorbidity, and prior treatment? The authors and the broader literature point to a layered set of mechanisms. On the provider side, clinicians may offer buprenorphine less often to patients of color, a pattern documented in emergency department studies and consistent with a bifurcated treatment system in which White patients are more often steered toward office-based medication while Black and Hispanic patients are channeled toward abstinence-oriented or criminal-legal pathways. On the structural side, counties with high levels of racial and ethnic segregation have less treatment capacity for opioid use disorder, meaning that even a motivated patient may leave a hospital without a nearby prescriber. Medicaid itself adds friction: prior authorization requirements and managed care formulary restrictions vary by state and can delay or block fills, and pharmacy deserts are more common in predominantly Black and Latino neighborhoods. Naloxone distribution, meanwhile, has historically under-reached communities of color even as fentanyl has made overdose risk universal.

The consequences of these gaps are measured in lives. Buprenorphine reduces mortality during treatment, and the period immediately after an overdose or hospital discharge is one of extreme vulnerability, with overdose risk elevated for weeks. Every failure to initiate or sustain medication during a transitional window compounds that risk. The study’s authors argue that improved transitional care, warm handoffs from emergency departments and hospitals to community-based treatment, overdose education, take-home naloxone, and follow-up appointments, combined with targeted Medicaid reforms such as streamlined coverage of medications and enhanced payment for transitional care management, could close the gap. The elimination of the federal buprenorphine waiver requirement, often called the MAT Act, has removed one prescriber-level barrier, but the new findings suggest that prescriber-level change alone will not be sufficient.

What makes this study resonate beyond the specialty literature is its scale and its consistency. Nearly a quarter of a million acute opioid-related events, spanning 19 states and four years, all point in the same direction: at the moments when the health system has the greatest leverage over the trajectory of opioid use disorder, Black and Hispanic patients are systematically less likely to receive and keep the treatment that best prevents death. The opioid crisis has often been described as having shifted demographically, with rising overdose rates among Black Americans in recent years, yet the treatment infrastructure has not kept pace with that shift. As policymakers weigh Medicaid reforms and health systems build out addiction consult services and emergency department buprenorphine programs, the study offers a clear benchmark: equitable access must be measured not just in who walks through the door, but in who leaves with a prescription filled, and who is still taking their medication six months later.

Subject of Research: Racial and ethnic disparities in buprenorphine and naloxone receipt and retention among Medicaid beneficiaries after acute opioid-related care

Article Title: Racial and Ethnic Disparities in Buprenorphine and Naloxone among Medicaid Beneficiaries after Emergency Department Visits and Hospitalizations

Article References: Khidir, H., Nedelec, L., Sebok-Syer, S. S., Sabbatini, A. K., Shin, I., Melnick, E. R., & Lin, M. P. (2026). Racial and Ethnic Disparities in Buprenorphine and Naloxone among Medicaid Beneficiaries after Emergency Department Visits and Hospitalizations. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10838-0

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10838-0

Keywords: opioid use disorder, buprenorphine, naloxone, Medicaid, health disparities, emergency department, hospitalization, treatment retention, overdose, addiction medicine, health equity, transitional care

The three-day rule is a provision of federal regulation that permits practitioners who are not affiliated with an OTP to administer methadone to a patient for the purpose of relieving acute withdrawal symptoms while arranging referral to a licensed program. The allowance is capped at three days, and it cannot be renewed within the same month. In practice, it has historically been used sparingly, because clinicians have worried about safety and because the short window seems ill-suited to overcoming the administrative delays that often accompany OTP enrollment. The new research, published in the journal Addiction Science & Clinical Practice, offers a detailed real-world test of the approach as implemented at the San Francisco General Hospital Bridge Clinic, a low-threshold service designed to meet patients where they are.

The study team, led by Sarah Rosenwohl-Mack of UCSF’s Department of Family and Community Medicine, conducted a retrospective case series covering every patient who initiated methadone under the three-day rule at the Bridge Clinic between June 2024 and July 2025. The setting is notable for an unusual piece of geography: the hospital also houses an opioid treatment program in the same building. When that program could not complete an intake, for example because a patient arrived outside scheduled intake hours or the program was at capacity, staff could refer the person down to the Bridge Clinic, where a dose of methadone could be started immediately under the three-day provision. This bidirectional referral pathway became the study’s central variable.

The researchers tracked two primary outcomes. The first was linkage to an OTP within seven days of receiving the initial Bridge Clinic dose, a window that extends beyond the three-day medication allowance and therefore captures whether the bridge actually carried patients to permanent care. The second was retention in OTP treatment at 30 days, a marker of early stability that addiction medicine researchers view as a meaningful predictor of longer-term benefit. Because methadone carries its own risks, particularly when combined with other sedatives, the team also built in a safety monitoring framework that reviewed urine drug screens, emergency department visits, hospitalizations within seven days, and Medical Examiner overdose reports.

The results are striking for a population that conventional systems routinely lose. Among 166 unique patients who received at least one dose of three-day methadone at the Bridge Clinic, 63 percent, or 104 individuals, successfully linked to an opioid treatment program within seven days. Of those who linked, 62 percent, or 64 patients, were still retained in treatment at the 30-day mark. In a field where attrition between first contact and enrollment has long been considered one of the most stubborn leaks in the continuum of care, the finding suggests that a short bridge of medication can hold a substantial fraction of patients long enough for the formal system to catch up with them.

The most consequential finding, however, concerned the direction of the referral. Using multivariable logistic regression to adjust for other factors, the researchers found that patients who arrived at the Bridge Clinic by referral from the co-located OTP had 3.1-fold higher odds of remaining in treatment at 30 days compared with patients who came through other routes. The interpretation is not that the referral itself dispensed a pharmacological benefit, but that the pathway reflects a coordinated system in which the OTP and the Bridge Clinic function as two doors into the same building of care. A patient handed off from the OTP arrives with an established clinical relationship, a documented treatment plan, and a clear route back, whereas a patient walking in cold must navigate enrollment largely on their own after the three-day window closes.

On the safety side, the record was clean in ways that will reassure clinicians who have hesitated to use the three-day rule. The study identified no methadone-related emergency department visits, no hospitalizations, and no deaths within 30 days of receiving methadone at the Bridge Clinic. The urine drug screen review, designed to flag unexpected results such as methadone positivity in patients not prescribed it or the absence of non-prescribed opioids suggesting diversion, surfaced only one notable case: a single patient who, on closer chart review, turned out to have already been enrolled in methadone treatment elsewhere before receiving a dose at the Bridge Clinic. That finding points to a practical quality-control challenge, ensuring that bridge dosing does not duplicate existing treatment, but it does not undermine the overall safety signal.

The technical logic of the intervention deserves attention. Methadone is a long-acting full mu-opioid receptor agonist with a half-life that supports once-daily dosing, which is precisely why it smooths the cycle of withdrawal and craving that drives much of the daily chaos in untreated opioid use disorder. When a patient presents in withdrawal, the clinical task is to provide enough of the medication to relieve symptoms without accumulating toxicity, which is why Bridge Clinic protocols begin with conservative doses and titrate carefully. The three-day rule fits neatly into this pharmacology: three days of supervised dosing is enough to stabilize a patient physiologically and to interrupt the withdrawal-driven urgency that otherwise pushes people back to fentanyl and other illicit opioids, while the referral machinery works in parallel to secure a permanent slot at an OTP.

The San Francisco team acknowledges intellectual debts in the paper, crediting the Faster Paths Emergency Opioid Withdrawal Protocol at Boston Medical Center, whose published approach informed the local protocol. That lineage matters because it illustrates how low-threshold models are spreading through a kind of open-source clinical adaptation, with programs borrowing and refining each other’s protocols rather than waiting for multi-year trials. The study itself was deemed exempt by the UCSF Institutional Review Board and used retrospectively collected anonymized data, a design that trades the rigor of randomization for the realism of observing how an intervention performs inside the ordinary friction of a public hospital.

The implications reach well beyond one clinic. Opioid treatment programs remain the only legal channel for methadone maintenance in the United States, and their geographic maldistribution means that many counties have no OTP at all. The three-day rule cannot substitute for structural reform, but the study demonstrates that when a low-threshold bridge service and a licensed OTP are deliberately networked, the rule becomes a functional handoff mechanism rather than a rarely used legal footnote. The 3.1-fold retention advantage associated with OTP referral suggests that the return on investment lies in building those connections, ensuring that every bridge dose is paired with a warm pathway back into licensed care. For a lethal epidemic that has proven resistant to conventional outreach, the message is deceptively simple: meet people in withdrawal with medication the same day, and engineer the system so that the door they entered stays open behind them.

Subject of Research: Three-day methadone bridging at a low-threshold clinic to improve linkage and retention in opioid treatment programs

Article Title: Implementing three-day methadone in a low-threshold Bridge Clinic: impact of OTP referral pathways on treatment retention

Article References: Rosenwohl-Mack, S., Suen, L. W., Hart, R., Steiger, S., Hom, J. K., & Snyder, H. (2026). Implementing three-day methadone in a low-threshold Bridge Clinic: impact of OTP referral pathways on treatment retention. Addiction Science & Clinical Practice. https://doi.org/10.1186/s13722-026-00725-8

Image Credits: AI Generated

DOI: 10.1186/s13722-026-00725-8

Keywords: methadone, opioid use disorder, opioid treatment program, Bridge Clinic, three-day rule, treatment retention, harm reduction, San Francisco General Hospital, low-threshold care, withdrawal management, addiction medicine, medication for opioid use disorder

Substance use disorders represent one of the most formidable public health burdens in the Americas, where they stand as the leading cause of premature death and disability. The scale of the problem is stark: substance use is implicated in a substantial share of deaths among the world’s adult population, and effective treatment remains one of the most powerful tools available for reducing that toll. Yet treatment only works if people stay in it. Dropout is a persistent and corrosive weakness across virtually every model of addiction care, shortening exposure to interventions, undermining therapeutic momentum, and returning patients to the very environments that may have fueled their substance use in the first place. Understanding who drops out, and when, has therefore become a central question for researchers and clinicians alike.

The new research, published in Addiction Science & Clinical Practice, turned to an unusually rich source of evidence: Chile’s national registry of patients receiving publicly funded treatment for substance use disorders between 2010 and 2019. The investigators focused on emerging adults, those aged 18 to 29, a developmental window marked by instability, identity formation, and heightened vulnerability to both substance use and treatment disengagement. From the registry they assembled a retrospective cohort of 23,979 young adults and classified each person’s living arrangement at the moment they entered treatment into three categories: living alone, living with family of origin, or living with a partner and children. The question was deceptively simple. Did the shape of a patient’s household predict how long they stayed in treatment?

Answering it rigorously required sophisticated statistical machinery. People who live alone are not randomly different from those who live with family; they may differ in age, severity of addiction, employment, education, mental health, and a host of other characteristics that independently influence retention. To disentangle these threads, the researchers used inverse probability of treatment weighting, a technique built on multinomial logistic propensity scores that statistically balances the comparison groups on observed baseline differences. Survival analysis methods, including weighted Kaplan–Meier estimation, were then applied to track how the probability of remaining in treatment evolved over time. The team also computed the restricted mean survival time, a measure that captures the average duration of retention within a defined window and offers an intuitive summary of the survival curves that complements traditional hazard-based approaches.

Crucially, the analysis was stratified by treatment setting, separating outpatient programs from inpatient and residential care, because the two environments place very different demands on patients. The results painted a consistent picture. Young adults living with their family of origin or with a partner and children had a higher probability of remaining in treatment than those living alone, and the gap was widest in inpatient programs. At six months, the probability of still being in treatment was 0.54 for those living with family of origin and 0.57 for those living with a partner or children, compared with just 0.41 for those living alone. At twelve months, the pattern held: 0.43 and 0.44 for the cohabiting groups against 0.33 for those living solo. In other words, nearly six in ten socially connected patients were still engaged at the six-month mark in inpatient care, while fewer than half of those living alone remained.

The restricted mean survival time analysis reinforced the message. Among inpatient participants, the one-year RMST reached 0.60 for those living with family of origin and 0.62 for those living with a partner or children, but only 0.49 for those living alone, a retention gap that translates into weeks of additional engagement over the first year of care. Notably, the two cohabiting groups did not differ from each other in the inpatient setting; whether the anchor was parents, siblings, or one’s own partner and children, the protective effect of shared living appeared comparable. Outpatient programs told a subtler story. There, the differences between living arrangements were modest, and the most consistent contrast emerged between those living with family of origin and those living with a partner and children, suggesting that the protective architecture of the household may interact with the intensity and structure of the treatment modality itself.

Why would a shared household buffer against dropout? The authors point to the central role of social bonds. Family members and partners can provide practical scaffolding, transportation to appointments, reminders, financial support, a stable place to sleep, as well as emotional accountability, the diffuse but powerful sense that someone notices when you fail to show up. For emerging adults, whose ties to education, employment, and institutions are often still fragile, these bonds may carry particular weight. Residential and inpatient treatment, which requires a deliberate withdrawal from daily life, may be especially difficult to sustain without a household invested in one’s return and recovery. Conversely, young adults living alone may face treatment environments that inadvertently ask them to be their own support system, a demand that substance use disorders themselves make harder to meet.

The study’s implications reach well beyond Chile. Many national treatment systems, including those in high-income countries, collect detailed clinical data on substance use severity, psychiatric comorbidity, and treatment modality, yet rarely capture living arrangements as a structured variable at intake. This research suggests that a single intake question, who do you live with, could help identify patients at elevated risk of early disengagement and trigger targeted supports, from peer outreach and case management to deliberate family involvement in treatment planning. The findings also resonate with systems and family therapy traditions that view addiction not merely as an individual pathology but as a condition embedded in relational networks. Interventions that strengthen those networks, or that compensate for their absence, may hold untapped value for the youngest and most precarious patients.

Certain caveats deserve emphasis. As a retrospective cohort study, the analysis can establish association but not causation; unmeasured characteristics, such as motivation for recovery, quality of family relationships, or neighborhood context, could partly explain the observed differences. Living arrangements were assessed at treatment entry and may have changed during follow-up. The study also examined public-sector treatment in a single country, and Chile’s specific service configuration may shape how household context interacts with care. Nevertheless, the sheer size of the cohort, the decade-long observation window, and the rigor of the statistical design give the findings unusual credibility for observational research in this field, and Chile’s advanced monitoring infrastructure makes the dataset one of the strongest of its kind in Latin America.

The broader lesson is one that clinicians and policymakers are increasingly being asked to internalize: recovery is not enacted in a vacuum. For young adults, the developmental crucible in which identities, careers, and relationships are forged, the presence of a stable relational anchor may be the difference between a treatment episode that endures and one that dissolves within months. As the authors conclude, effective strategies for substance use disorders must take social support into account, recognizing the potential positive impact of familial and relational bonds during the critical phase of emerging adulthood. In a decade of data from nearly 24,000 patients, the signal is difficult to ignore: the people waiting at home may be among the most powerful, and least expensive, therapeutic assets a treatment system has.

Subject of Research: The association between living arrangements and time to dropout from substance use disorder treatment among emerging adults in Chile.

Article Title: Association between living arrangements and time to drop out in patients between 18 and 29 years of age, under treatment for substance abuse disorders in Chile, 2010–2019

Article References: Association between living arrangements and time to drop out in patients between 18 and 29 years of age, under treatment for substance abuse disorders in Chile, 2010–2019. (n.d.). https://doi.org/10.1186/s13722-026-00721-y

Image Credits: AI Generated

DOI: 10.1186/s13722-026-00721-y

Keywords: substance use disorders, treatment dropout, living arrangements, emerging adults, treatment retention, social support, inpatient treatment, outpatient treatment, Chile, survival analysis, family bonds, public health